Extensive-Stage Small Cell Lung Cancer
Conditions
Brief summary
Number of participants with adverse events (AEs), Number of participants with serious adverse events (SAEs), Discontinuations due to AEs, Number of participants who died due to AEs, Number of participants with laboratory toxicity grade shift from baseline, Progression Free Survival
Detailed description
Maximum observed serum concentration(Cmax), Time of maximum observed serum concentration(Tmax), Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration(AUC(0-T)), Observed serum concentration at the end of a dosing interval(Ctau), Area under the concentration-time curve in 1 dosing interval(AUC(TAU)), Characterization of Immunogenicity
Interventions
None listed
Sponsors
Bristol Myers Squibb International Corporation
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events (AEs), Number of participants with serious adverse events (SAEs), Discontinuations due to AEs, Number of participants who died due to AEs, Number of participants with laboratory toxicity grade shift from baseline, Progression Free Survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Maximum observed serum concentration(Cmax), Time of maximum observed serum concentration(Tmax), Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration(AUC(0-T)), Observed serum concentration at the end of a dosing interval(Ctau), Area under the concentration-time curve in 1 dosing interval(AUC(TAU)), Characterization of Immunogenicity | — |
Countries
Spain
Outcome results
None listed